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Abstract
Background: Abnormal one-carbon metabolism may lead to general genomic (global) hypomethylation, which may
predispose an individual to the development of colorectal neoplasia.
Methods: We evaluated the association between pre-diagnostic leukocyte genomic DNA methylation level and the risk of
colorectal cancer in a nested case-control study of 358 colorectal cancer cases and 661 matched controls within the all-
female cohort of the Nurses’ Health Study (NHS). Among control subjects, we further examined major plasma components
in the one-carbon metabolism pathway in relation to genomic DNA methylation level. Liquid chromatography/tandem
mass spectrometry was used to examine leukocyte genomic DNA methylation level. We calculated odds ratios (ORs) and
95% confidence intervals (95% CIs) using logistic regression.
Results: Overall genomic DNA methylation level was not associated with the risk of colorectal cancer (p for trend, 0.45).
Compared with women in the lowest quintile of methylation, the multivariate OR of colorectal cancer risk was 1.32 (95% CI,
0.82–2.13) for those in the highest quintile. We did not find significant associations between major plasma components of
one-carbon metabolism or risk factors for colorectal cancer and genomic DNA methylation level (all p for trend .0.05). Also,
neither one-carbon metabolism-related plasma components nor well-known risk factors for colorectal cancer modified the
association between genomic DNA methylation level and the risk of colorectal cancer (all p for interaction .0.05).
Conclusions: We found no evidence that hypomethylation of leukocyte genomic DNA increases risk of colorectal cancer
among women. Additional studies are needed to investigate the association between pre-diagnostic genomic DNA
methylation level and colorectal cancer risk among diverse populations.
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Introduction
One-carbon metabolism, or methyl-group metabolism, is
a critical pathway in cancer epigenetics [1]. It comprises a network
of interrelated biochemical reactions involved in the transfer of
methyl groups from one compound to another, which among
other effects can also affect the level of DNA methylation.
Abnormal one-carbon metabolism may result in general genomic
(global) hypomethylation, which may predispose an individual to
the development of neoplasia [2]. Few epidemiologic studies have
examined pre-diagnostic genomic DNA methylation status in
white blood cells in relation to cancer risk. A cross-sectional study
found that higher genomic methylation of leukocyte DNA is
associated with a reduced risk of colorectal adenoma, a precursor
for colorectal cancers [3].
We evaluated the influence of leukocyte genomic DNA
methylation status and its interaction with one-carbon metabo-
lism-related nutrients, genetic polymorphisms, and other factors
on the risk of colorectal cancer in a nested case-control study
within the Nurses’ Health Study (NHS).
Materials and Methods
Study Population
The NHS enrolled 121,700 female registered nurses aged 30–55
years in 1976; for more detail, please refer to [4]. We have sent
follow-up questionnaires to the cohort biennially to update
information regarding lifestyle factors and to ascertain new
diagnoses of major illnesses. The follow-up rate for this cohort
remains above 90% [5]. In 1989–90, we collected blood samples
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collected in tubes with heparin and sent to us by overnight
courier in chilled containers. On receipt, the bloods were
centrifuged, aliquoted, and stored at 270uC.
The procedures and protocols of the study were approved by
the Institutional Review Boards at Brigham and Women’
Hospital.
Selection of Colorectal Cancer Cases and Controls
We requested permission from cohort members who reported
colorectal cancer on our biennial questionnaires to obtain medical
records and pathology reports. We identified fatal cases from the
National Death Index and from next-of-kin [6]. Study physicians
blinded to exposure data reviewed all medical records to confirm
cases of colorectal cancer. We included incident colorectal cancer
cases who had provided a blood sample prior to cancer diagnosis.
We excluded the small number of cancers that were not
adenocarcinomas as well as carcinomas in situ. We randomly
selected one or two controls within the same cohort from
participants who had also provided blood samples but were free
of colorectal cancer at the time when the case was diagnosed.
Controls were matched to each case by age (within 3 years of
birth), month/year of blood sampling (95% of cases and controls
were matched within one month of blood sampling), and fasting
status (,8 versus $8 hours since last meal). In total, 358 incident
colorectal cancer cases diagnosed after the 1990 blood collection
until October 2008 and 661 matched controls were included in
our analysis.
Documentation of Life-style and Genetic Data
For the cases and controls, dietary data have been collected.
Briefly, a semiquantitative food-frequency questionnaire (FFQ)
with approximately 60 items was sent to the entire NHS cohort in
1980. An expanded FFQ with approximately 130 food items was
administered to women in 1984, 1986, and every 4 years
thereafter. Participants were asked how often on average they
had consumed each type of food or beverage, including alcoholic
beverages (beer, wine, and liquor) during the past year. Serving
sizes were specified for each food in the FFQ. The questionnaire
had nine possible responses, ranging from never or less than once
per month to six or more times per day. Responses on frequencies
of a specified serving size for each food item were converted to
average daily intakes. Quantities of nutrients from foods were
calculated by multiplying the reported frequency of each food by
the nutrient content of one serving of that food primarily on the
basis of the US Department of Agriculture Nutrient Database [7].
For each nutrient, energy intake was adjusted for using the
nutrient residual method [8].
Similarly, nondietary data have also been collected prospec-
tively for both cases and controls. Briefly, information on weight,
physical activity, aspirin use, history of endoscopy, and post-
menopausal hormone use was updated roughly every 2 years.
Information on family history of colorectal cancer in parents or
siblings was obtained in the 1982 questionnaire and was updated
in 1988, 1992, 1996, and 2000. The average number of cigarettes
smoked per day when subjects started to smoke, the average
number of cigarettes smoked per day in the first 5 years of
smoking, the age when subjects last smoked, and height were
assessed at baseline.
For a subset of the cases and controls in this study, we have also
assessed the plasma levels of major components in the one-carbon
metabolism pathway, including folate, vitamin B6, vitamin B12,
and homocysteine [9]. In brief, plasma concentrations of folate
and vitamin B12 were determined using a radioassay kit (Bio-Rad,
Richmond, CA), which uses a dual-radioisotope competitive
protein-binding assay. The kit simultaneously measures plasma
folate and vitamin B12. We used plasma concentrations of
pyridoxal 59-phosphate (PLP) to determine vitamin B6 levels,
because PLP is the main active form of vitamin B6. PLP
concentrations were determined using an enzymatic procedure
based on radioactive tyrosine and the apoenzyme tyrosine
decarboxylase, as described by Shin et al. [10]. Total plasma
homocysteine and cysteine concentrations are measured using
high-performance liquid chromatography with fluorescence de-
tection as described by Araki and Sako [11]. The mean coefficients
of variation for 75 pairs of replicate plasma samples in the NHS
were 6.5% for folate, 7.2% for vitamin B6, 7.3% for vitamin B12,
and 7.9% for homocysteine [12].
Methylene-tetrahydrofolate reductase (MTHFR) is a critical
enzyme in the one-carbon metabolism. Two nonsynonymous
single nucleotide polymorphisms (SNPs) in the MTHFR gene
(C677T [rs1801133] and A1298C [rs1801131]) have previously
been reported to alter MTHFR activity, and are also associated
with risk of colorectal neoplasia [13,14,15]. For these two SNPs in
the MTHFR gene, we have previously ascertained their genotypes
in a subset of the cases and controls in this study [16]. Briefly, these
two SNPs were genotyped by the 5 nuclease assay (TaqManH),
using the ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems, Foster City, CA). TaqManH primers and
probes were designed using the Primer ExpressH Oligo Design
software v2.0 (ABI PRISM). Laboratory personnel were blinded to
case-control status, and 10% blinded quality-control samples
(duplicated samples) were inserted to validate genotyping proce-
dures; concordance for the blinded quality-control samples was
100%. Primers, probes, and conditions for the genotyping assay
are available upon request. We confirmed that these two SNPs
were in Hardy-Weinberg equilibrium among the controls.
Genomic DNA Methylation Assay
Laboratory personnel were blinded to case-control status, and
the matched cases and controls were handled identically and
together, shipped in the same batch, and assayed in the same
analytical run. In addition, the order within each case-control pair
was random.
A liquid chromatography/tandem mass spectrometry (LC/MS/
MS) method was used to determine leukocyte genomic DNA
methylation status [17] using the ABI 3200 QTRAP LC/MS/MS
from Applied Biosystems. Briefly, 100 nanograms of DNA was
enzymatically hydrolyzed by sequential digestion with three
nucleases. DNA hydrolysates were then injected onto an analytic
column and subsequently separated by reversed-phase high-
performance liquid chromatography in isocratic mode. The four
major DNA bases and 5-methyl-29-deoxycytidine were resolved
and eluted in a short time run. 5-methyl-29-deoxycytidine was
identified by spectral analysis of chromatographic peaks by
isotope-labeled compounds as internal standard. The absolute
amount (in nanograms) of 5-methyl-29-deoxycytidine (mCyt) per
100 nanograms of DNA was determined. Percent genomic DNA
methylation status was defined as the percent of mCyt in total Cyt
and was used for the statistical analyses. For the percent genomic
DNA methylation level, the coefficient of variance (CV) was 4%
and intraclass correlation coefficient (ICC) was 0.34.
Statistical Analyses
We categorized the participants into quintiles based on percent
genomic DNA methylation level, using the first (lowest) quintile as
the reference group. We used conditional logistic regression to
estimate odds ratios (ORs) and corresponding 95% confidence
Genomic DNA Methylation and Colorectal Cancer
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ation status and total colorectal cancer risk. Multivariate ORs
were obtained from the conditional logistic regression models,
adjusting for known or suspected colorectal cancer risk factors.
Tests for trend were conducted by assigning the median value of
each quintile of methylation status among controls to both cases
and controls in each category and modeling it as a continuous
variable.
To determine whether the association between genomic
methylation status and colorectal cancer risk differed by levels of
plasma folate or homocysteine, total folate intake or alcohol
consumption, smoking status, family history of colorectal cancer,
age at blood draw, year of diagnosis, as well as two SNPs in the
MTHFR gene (C677T [rs1801133] and A1298C [rs1801131]), we
conducted analyses stratified by these variables. The statistical
significance of interaction was assessed by adding cross-product
terms of these variables and methylation status into the logistic
regression model, adjusting for matching factors as well as risk
factors for colorectal cancer.
Among control subjects, a linear regression model was
employed to examine the association between genomic methyla-
tion status and major factors involved in one-carbon metabolism
and known and suspected risk factors for colorectal cancer (plasma
folate, vitamin B6, vitamin B12, homocysteine, total folate or
alcohol intake, smoking status, family history of colorectal cancer,
age at blood draw, as well the two SNPs in the MTHFR gene).
Linear regression models were adjusted for matching factors as
well as risk factors for colorectal cancer. To attenuate the influence
of extreme values of the components, we calculated the geometric
mean of the methylation levels and corresponding 95% CIs for
each level of variables and modeled it as a continuous variable. For
each one-carbon component, tests for trend were conducted by
modeling the median value of each quintile as a continuous
variable. All statistical analyses were two-sided and carried out
using SAS V9.2 (SAS Institute, Cary, NC). A p-value,0.05 was
considered statistical significant.
Results
The baseline characteristics of the 358 colorectal cancer cases
and 661 controls are presented in Table 1. The mean age at
diagnosis of colorectal cancer cases was 68.3 years. Compared
with controls, colorectal cancer cases were more likely to have
family history of colorectal cancer, more likely to smoke,
consumed higher amounts of alcohol, and had lower intakes of
calcium, vitamin D, and folate, and were less physically active.
Among controls, the level of these colorectal cancer-related factors
was not significantly altered according to quintiles of genomic
DNA methylation level (Table 2).
Overall the percent genomic DNA methylation levels were not
associated with risk of colorectal cancer (Table 3). Compared with
women in the lowest quintile of methylation, the multivariate OR
of colorectal cancer risk was 1.32 (0.82–2.13) for those in the
highest quintile (p for trend, 0.45). Similarly, we did not find
significant associations between methylation status and risk of
colorectal cancer by subsites (i.e., colon, rectum, proximal colon,
and distal colon) (Table S1).
The association between methylation status and colorectal
cancer risk did not vary by either one-carbon metabolism-related
factors or well-known risk factors for colorectal cancer (all p for
interactions .0.05) (Table S2).
We further examined the association of major components of
the one-carbon metabolism and colorectal cancer-related factors
with genomic DNA methylation status (Table S3). None of these
variables was associated with methylation status (all p for trends
.0.05).
In colorectal tumor tissue from a subset of the colorectal cancer
cases [18,19], we assessed levels of long interspersed nucleotide
element-1 (LINE-1) methylation, which may be correlated with
global DNA methylation levels. We evaluated the correlation
between leukocyte genomic DNA methylation levels and tumor
LINE-1 methylation levels among the cases with LINE-1 values;
the Pearson correlation coefficient was 0.11 (p=0.19) in 141
samples.
Discussion
DNA methylation plays critical mechanistic roles in gene
regulation and cellular differentiation. Preserving the patterns of
DNA methylation is a major factor in the epigenetic control of
genomic stability and the regulation of gene transcription [20,21].
In eukaryotic cells, DNA methylation occurs at the carbon-5
position of cytosine, i.e., a methyl group is transferred from the
methyl donor S-adenosylmethionine to the cytosine-5 carbon by
DNA methyltransferases. Those methyltranferases predominantly
recognize the sequence of cytosine-guanine (CpG), and over 70%
of the cytosine residues in CpG dinucleotides of mammalian
genomic DNA are methylated [22].
An altered genomic DNA methylation profile is frequently
found in cancers. Previous studies have shown that abnormal
DNA methylation is common in neoplastic cells, including
widespread genomic hypomethylation and hypermethylation of
CpG clusters known as CpG islands, mostly residing within gene
promoter regions [22]. Such changes in DNA methylation can
contribute to carcinogenesis by promoting the expression of
oncogenes and transcriptional silencing of tumor suppressor genes
and/or making critical tumor suppressor genes more susceptible to
DNA damage [2,23,24].
Genomic DNA hypomethylation is an early and consistent
event in colorectal carcinogenesis [25,26]. For example, a case-
control study of 35 cases of colorectal adenoma (a premalignant
condition of colorectal cancer) found that both colonic and
leukocyte DNA hypomethylation were significantly associated with
an increased risk of colorectal adenoma [27]. Similarly, using the
same LC/MS method used here for methylation assay, a cross-
sectional study conducted by Lim et al. found that leukocyte
genomic DNA hypomethylation was associated with an increased
risk of colorectal adenoma [3]. Compared with those in the highest
tertile of genomic methylation, participants in the lowest tertile
had an OR of 5.88 (95% CI, 2.04–16.67) for the risk of colorectal
adenoma. In contrast, for colorectal cancer, a case-control study of
28 cases and 76 controls did not find an association with either
colonic or leukocyte genomic DNA methylation level [27]. We
also found no association between pre-diagnostic genomic DNA
methylation status and colorectal cancer risk. Similarly, using
essentially the same LC/MS method, Huang et al. found no clear
association between leukocyte methylation level and colorectal
cancer risk [28]. We note, however, that the evidence regarding
genomic DNA hypomethylation and cancer risk is controversial,
because regional hypermethylation may also be related to
increased cancer risk [22,29,30,31].
One issue to discuss is why our results differ from those of Lim
et al. [3]. We utilized the same assay, and although the absolute
methylation levels were slightly lower in our study, the ranges were
very similar. Thus, the ranking of the subjects should be the same.
Interestingly, Lim et al. [3] detected the association with
methylation level only in non-advanced adenomas, though they
had limited numbers of advanced adenomas. It is therefore
Genomic DNA Methylation and Colorectal Cancer
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a sub-group of adenomas less likely to progress to malignancy.
General genomic DNA hypomethylation could to some extent
be derived from abnormal one-carbon metabolism [2]. One of the
central elements in the methyl-group metabolism pathway is
folate, which donates a single carbon to homocysteine to form
methionine, which is then converted to S-adenosylmethionine, to
which DNA transfers the methyl group [32,33,34]. To date, folate
and other major factors involved in one-carbon metabolism
including vitamin B6, vitamin B12, homocysteine, and MTHFR (a
major folate metabolic enzyme) have been associated with several
cancer sites including colon, breast, pancreas, cervix, bronchus,
and leukaemia [35]; the evidence of an association with colorectal
cancer is most compelling in both animal and human studies [36].
Table 1. Characteristics of colorectal cancer cases and controls in the nested case-control study within the Nurses’ Health Study.
Characteristic Cases (n=358) Controls (n=661)
Age at diagnosis (years, mean) 68.3 NA
Age at blood draw (years, mean) 59.0 59.0
Regular aspirin use (%) 46.4 46.4
Body mass index (kg/m
2, mean)
a 25.9 25.4
Physical activity (METs -hours/wk, mean)
b 16.0 17.0
Colorectal cancer in a parent or sibling (%) 15.6 14.1
Former or current smoker (%) 58.1 56.7
Alcohol consumption (g/day, mean) 5.9 5.2
Former or current postmenopausal hormone use (%) 50.8 50.5
Beef, pork, or lamb as a main dish (servings/wk, mean) 1.1 1.1
Total calcium intake (mg/, mean)
c 747.9 757.2
Total vitamin D intake (IU/d, mean)
c 216.8 227.1
Total folate intake (mg/d, mean)
c 424.5 456.2
aBody mass index is weight in kilograms divided by the square of the height in meters.
bMET denotes metabolic equivalent. Met –hours=sum of the average time/wk in each activity x MET value of each activity. One MET, the energy spent sitting quietly, is
equal to 3.5 ml of oxygen uptake per kilograms of body weight per minute for a 70-kg adult.
cNutrient values (calcium, vitamin D, and folate) represent the mean of energy-adjusted intakes.
doi:10.1371/journal.pone.0059455.t001
Table 2. Characteristics of colorectal cancer controls by levels of leukocyte genomic DNA methylation in a case-control study
nested within the Nurses’ Health Study.
Methylation (quintiles; range, % )
Characteristic 1 2 3 4 5
(3.628–4.107) (4.108–4.196) (4.198–4.272) (4.273–4.353) (4.354–4.788)
Number of controls 131 134 131 133 132
Age at blood draw (years, mean) 58.8 59.6 58.8 59.3 58.3
Regular aspirin use (%)
a 41.0 42.8 53.7 44.9 47.6
Body mass index (kg/m
2, mean)
b 25.7 25.1 25.6 25.7 25.2
Physical activity (METs -hours/wk, mean)
c 14.8 16.8 18.5 17.8 16.6
Colorectal cancer in a parent or sibling (%) 9.6 17.6 14.6 16.3 13.0
Former or current smoker (%) 52.6 63.3 53.1 58.8 56.4
Alcohol consumption (g/d, mean) 4.4 6.0 5.4 5.1 5.2
Former or current postmenopausal hormone use (%) 45.1 53.7 51.0 51.2 51.4
Beef, pork, or lamb as a main dish (servings/wk, mean) 1.1 1.0 1.0 1.1 1.0
Total calcium intake (mg/d, mean)
d 761.0 736.4 749.4 783.2 774.0
Total vitamin D intake (IU/d, mean)
d 217.1 221.5 236.3 239.8 223.1
Total folate intake (ug/d, mean)
d 449.5 467.9 442.8 450.0 469.1
aRegular aspirin use was defined as intake of at least two 325-mg tablets per week in the NHS.
bThe body mass index is weight in kilograms divided by the square of the height in meters.
cMET denotes metabolic equivalent. Met -hours=sum of the average time/wk in each activity x MET value of each activity. One MET, the energy spent sitting quietly, is
equal to 3.5 ml of oxygen uptake per kilograms of body weight per minute for a 70-kg adult.
dNutrient values (calcium, folate, and vitamin D) represent the mean of energy-adjusted intakes.
doi:10.1371/journal.pone.0059455.t002
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metabolism may alter the status of genomic DNA methylation
and further influence colorectal carcinogenesis [2,36]. For in-
stance, a previous study of 33 elderly women found that moderate
folate depletion reduces leukocyte genomic DNA methylation level
[37]. In addition, two SNPs in the MTHFR gene (C677T and
A1298C) have been associated with genomic DNA methylation
levels [13,38,39]. Carriers of the 677TT genotype had lower
leukocyte genomic DNA methylation level than those with the
677CC wild-type genotype, and genomic DNA methylation level
was also associated with an increased risk of colorectal adenoma
and cancer, especially in subjects with lower folate levels
[14,38,39]. Moreover, a recent study by Huang et al. [28]
reported an inverse association between natural folate intake and
colorectal cancer among individuals with the highest methylation
level (p for interaction, 0.003). In our study, major one-carbon
metabolism components including folate were not found to affect
leukocyte genomic DNA methylation status or the association
between genomic DNA methylation level and colorectal cancer
risk. However, it has to be noted that some of the markers in the
one-carbon metabolism are involved not only in DNA methylation
but also in multiple other pathways [40].
The LC/MS method used in this study to assess global DNA
methylation level in blood leukocytes differs from the assessment of
LINE-1 methylation status in a subsample of colorectal tumor
tissues [19]. LINE-1 CpG island methylation status was measured
using bisulfite-treated DNA, utilizing PCR and subsequent
pyrosequencing. Methylation levels of LINE-1 was calculated by
the amounts of ‘‘C’’ relative to the sum of the amounts of ‘‘C’’ and
‘‘T’’ at each CpG site. We note that the methylation levels in
blood versus tissue specimens have different implications. The
methylation status in blood may represent the body’s systemic
methylation status rather than the status in a specific organ. We
did not find a significant relationship between global DNA
methylation level in blood and LINE-1 methylation level in
colorectal tumor tissue. A recent study of bladder cancer [41]
found that the mean percent LINE-1 methylation level measured
in buffy coat was correlated with that in serum, but not with that in
tumor tissue, suggesting that methylation level measured in blood
may not reflect tissue level.
We acknowledge that there are various methods for assessing
genomic DNA methylation status in blood. However, the current
study as well as the other two studies [3,28] conducted to date on
the association between genomic DNA methylation level in blood
leukocyte and the risk of colorectal adenoma or colorectal cancer
have used essentially the same LC/MS method to measure global
DNA methylation level. Furthermore, using the same method,
neither our study nor the study conducted by Huang et al. [28]
found a significant association between pre-diagnostic genomic
DNA methylation level and colorectal cancer risk, while the study
conducted by Lim et al. [3] identified an association between
higher genomic methylation of leukocyte DNA and reduced risk of
colorectal adenoma.
Our study has several strengths. First, we measured pre-
diagnostic leukocyte genomic DNA methylation level among
individuals from a large prospective cohort, ensuring that the
measure of DNA methylation level preceded development of
colorectal cancer by up to 32 years. Second, our case-control study
was nested within a large well-characterized cohort in which
matched controls were selected from the same cohort, minimizing
the likelihood of population stratification or selection bias [42].
Third, repeated measurements of both dietary and non-dietary
factors allowed us to use repeated and updated information on
those confounding factors, reducing the likelihood of measurement
error.
A potential limitation of this study is the lack of generalizability
of the study population, because our participants are an older,
non-random sample of US women. However, it is unlikely that the
biological relation between DNA methylation level and colorectal
cancer risk in our cohort will differ appreciably from US women in
general. In previous analyses from the NHS, we detected
associations for colorectal cancer and other illnesses that are very
similar to those found in other broadly based US populations.
Though residual confounding is a concern in observational studies,
adjustment for multivariate colorectal cancer risk factors only
minimally influenced our findings, suggesting little potential for
residual or uncontrolled confounding. The statistical power for the
sub-groups analyses was modest; additional studies are warranted
to confirm the associations observed in the present study.
In conclusion, our study does not support the hypothesis that
pre-diagnostic hypomethylation of leukocyte genomic DNA
increases risk of colorectal cancer. Additional studies are needed
to investigate the association between pre-diagnostic genomic
DNA methylation level and colorectal cancer risk among diverse
populations.
Supporting Information
Table S1 Association between genomic DNA methyla-
tion level and the risk of colorectal cancer according to
subsites of large bowel.
(DOCX)
Table S2 Risk for colorectal cancer according to
genomic DNA methylation status, stratified by one-
carbon metabolism-related factors.
Table 3. Association between leukocyte genomic DNA methylation level and colorectal cancer risk in the nested case-control
study.
Methylation (%)
1
st quintile
(3.628–4.107)
2
nd quintile
(4.108–4.196)
3
rd quintile
(4.198–4.272)
4
th quintile
(4.273–4.353)
5
th quintile
(4.354–4.788) P for trend
No. of cases/controls 64/131 82/134 69/131 66/133 77/132
Median (%) 4.03 4.16 4.24 4.31 4.43
Crude OR (95% CI) 1.00 1.37 (0.89–2.09) 1.18 (0.75–1.83) 1.07 (0.68–1.68) 1.29 (0.82–2.03) 0.50
Multivariate OR (95% CI) 1.00 1.32 (0.84–2.08) 1.25 (0.78–2.01) 1.09 (0.68–1.75) 1.32 (0.82–2.13) 0.45
Multivariate ORs are adjusted for race, height (continuous), pack-years of smoking (continuous), body mass index (continuous), physical activity (in quartiles), family
history of colorectal cancer (yes or no), history of colonoscopy or sigmoidoscopy (yes or no), alcohol intake (continuous), intake of red and processed meat (in quartiles),
vitamin D intake (continuous), calcium intake (continuous), and aspirin use (non-users vs. ever users).
doi:10.1371/journal.pone.0059455.t003
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Table S3 Association of one-carbon metabolism and
colorectal cancer-related factors with percent genomic
DNA methylation levels among controls.
(DOCX)
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